GLINT: GlucoCEST in neoplastic tumors at 3 T—clinical results of GlucoCEST in gliomas

Benjamin Bender(University of Tübingen), Tobias Lindig(University Children's Hospital Tübingen), Klaus Scheffler(University Hospital of Basel), Jens Schittenhelm(Brain (Germany)), Xavier Golay(Gold Standard Simulations (United Kingdom)), Kai Herz(Max Planck Institute for Biological Cybernetics), Moritz Zaiß(Friedrich-Alexander-Universität Erlangen-Nürnberg), V Richter(STZ eyetrial), Ulrike Ernemann(University of Tübingen), A Deshmane(Max Planck Institute for Biological Cybernetics), Ghazaleh Tabatabai(Goethe University Frankfurt), Mina Kim(University College London), Marco Skardelly(University Children's Hospital Tübingen)
Magnetic Resonance Materials in Physics Biology and Medicine
December 10, 2021
10.1007/s10334-021-00982-5
Cited by 17

Related Papers

Recommended implementation of arterial spin‐labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia
|Magnetic Resonance in Medicine|2014|2.2k
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581
Pros and cons of ultra-high-field MRI/MRS for human application
|Progress in Nuclear Magnetic Resonance Spectroscopy|2018|542
Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications
|Radiology|2016|509
Amide proton transfer imaging of human brain tumors at 3T
|Magnetic Resonance in Medicine|2006|341